login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock News
NASDAQ:XOMAO -
US98419J4040
25.4999
USD
-0.01 (-0.03%)
Last: 9/5/2025, 4:30:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
XOMAO Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
3 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
16 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
24 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
24 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
25 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
25 days ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
TSBX
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
a month ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V.
- Mentions:
XOMA
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
a month ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V.
- Mentions:
XOMA
LVTX
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
a month ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
a month ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
HLVX
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
2 months ago - By: XOMA Royalty Corporation; Turnstone Biologics Corp.
- Mentions:
XOMA
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
2 months ago - By: XOMA Royalty Corporation; Turnstone Biologics Corp.
- Mentions:
XOMA
TSBX
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
3 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
3 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
3 months ago - By: XOMA Royalty Corporation; BioInvent
- Mentions:
XOMA
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
3 months ago - By: XOMA Royalty Corporation; BioInvent
- Mentions:
XOMA
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
4 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
4 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
4 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
4 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
5 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
5 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
5 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
5 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
6 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
6 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
6 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
6 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
6 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at Investor Conferences in March
6 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at Investor Conferences in March
7 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
7 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
9 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
9 months ago - By: XOMA Royalty Corporation
- Mentions:
XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends
9 months ago - By: XOMA Corporation
- Mentions:
XOMA
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
9 months ago - By: XOMA Corporation
- Mentions:
XOMA
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
10 months ago - By: XOMA Corporation
- Mentions:
XOMA
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
10 months ago - By: XOMA Corporation
- Mentions:
XOMA
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
11 months ago - By: XOMA Corporation
- Mentions:
XOMA
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Please enable JavaScript to continue using this application.